Shanghai Kejun Medical Technology

Shanghai Kejun Medical Technology is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics for oncology, with a particular emphasis on the RAS/MAPK signaling pathway. The company's lead programs target various KRAS mutations, including G12D and G12V, which are prevalent in difficult-to-treat cancers such as pancreatic and colorectal carcinoma. Kejun Medical utilizes a structure-based drug design approach to develop highly selective inhibitors aimed at overcoming resistance mechanisms in solid tumors. By targeting key nodes in oncogenic pathways, the company seeks to provide next-generation precision medicines for patients with high unmet medical needs.